In 2022, James C. Mullen earned $487.94K in total compensation at Editas Medicine, including $153.85K salary and $315.62K bonus. Led Editas Medicine as CEO for 1 years.
Compensation History
Annual executive compensation data for James C. Mullen, including salary, bonuses, and stock awards.
Year
2022
Total Compensation
$487.94K
Salary
$153.85K
Bonus
$315.62K
Other
$18.48K
Salary
$153.85KBoard Justification
Biogen's compensation philosophy emphasizes pay-for-performance, aligning executive compensation with company performance and shareholder interests, while also considering market competitiveness.
Bonus
$315.62KBoard Justification
Prorated bonus for the period of employment in 2022, based on a target bonus of 150% of base salary and a Company Multiplier of 100%.
Other Compensation
$18.48KBoard Justification
Includes life insurance premiums and other benefits.
Restricted Stock
Board Justification
No stock was vested in 2022 as the focus is on stock options and performance-based awards.
Performance Metrics
Financial performance metrics included revenue and non-GAAP diluted EPS targets, as well as strategic goals related to Alzheimer's disease initiatives and pipeline development.
James C. Mullen
Ex-CEO of Editas Medicine
Education
N/A
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
Born
February 1, 1958 - 67 years ago
CEO of Editas Medicine for
1 year 3 months (Feb 2021 - Jun 2022)
Previous Experience
CEO of Patheon N.V.; President and CEO of Biogen Inc.; various operating positions at Biogen.
Holdings
Track James C. Mullen's stock holdings and portfolio value over time.
Insider Trading
James C. Mullen's recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare James C. Mullen with competitor CEOs and industry peers.